NEW YORK (GenomeWeb News) – Illumina reported after the close of the market Tuesday that its third-quarter revenues rose 5 percent, and it swung from a loss to a profit.

The San Diego-based firm missed analysts' consensus estimate, and its shares plunged 21 percent to $32.99 in after-hours trade — though its shares were trading at $35.23 in early Wednesday trade. The shortfall was due to a few issues, including a quality control issue related to sequencing reagent kits that could impact Illumina's Q4 revenues as well.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.